Skip to main content

  • Did you know?
    Depending on your degree of allergies, allergen avoidance steps and medications by themselves may not be entirely effective in managing your symptoms.
    View Pollen Count

Doctor examining with a microscope

Resources

Clinical Research

Interested in one of the Trials?

Patients may be financially compensated for their time and travel, and may receive their existing asthma medications at no cost for the duration of the study.

First Name *
Last Name *

For more information, please email our clinical research coordinator, Kelli VanNess, at kelli@somnos.com or Emily Waltman at emily@somnos.com or call 402-325-3803.

Currently Enrolling Studies

Drug research plays a vital role in developing future treatments for allergic disorders. At AAIA, we are committed to participating in clinical research to help find better therapies for those suffering from allergies and asthma. Below is a description of clinical trials for which we are currently enrolling patients.

  1. Phase 3 Research Study: For patients with severe, uncontrolled asthma (treatment period of 52 weeks)
  2. Phase 3 Research Study: For patients with severe, uncontrolled asthma (treatment period of 24 weeks)
  3. Phase 3 Research Study: For children 6-11 years with persistent, uncontrolled asthma (treatment period of 52 weeks)
  4. Phase 4 Research Study: Observational study of patients with a diagnosis of asthma and/or COPD (observation period of 3 years)
  5. Phase 3 study to evaluate the effect of trial medication on the AAER lung function, and asthma control in adults and adolescents with uncontrolled asthma. Male or Female 12-80 years of age
  6. Phase 3 study to evaluate the effect of trial medication on patients with severe nasal polyps. Male or Female 18-75 years of age
  7. Phase 3 study comparing study drug to Spiriva Respimat in subjects with persistent asthma. Male or Female 18 years of age or older
  8. Phase 3 study for patients with inadequately controlled asthma
  1. Phase 3 Research Study: For patients with severe, uncontrolled asthma (treatment period of 52 weeks)

    1. Subjects ≥12 years of age with severe asthma requiring medium to high-dose inhaled corticosteroids plus a second or third asthma controller

    2. ​Two or more asthma exacerbations in the previous 12 months requiring treatment with systemic corticosteroids

    3.​ FEV1 of ≥40% and ≤80% (≤90% for patients aged 12-18 years)

    4.​Current smokers and ex-smokers with >10 pack-year smoking history are not eligible

  2. Phase 3 Research Study: For patients with severe, uncontrolled asthma (treatment period of 24 weeks)

    1. Subjects 18-75 years of age with severe asthma requiring medium to high-dose inhaled corticosteroids plus a second asthma controller in the previous 12 months

    2. Two or more asthma exacerbations in the previous 12 months requiring treatment with systemic corticosteroids

    3. ​Pre-screening FEV1 <80% of predicted

    4. Current smokers and ex-smokers with >10 pack-year smoking history are not eligible

  3. Phase 3 Research Study: For children 6-11 years with persistent, uncontrolled asthma (treatment period of 52 weeks)

    1. Subjects 6-11 years of age with persistent asthma for at least 12 months

    2. At least 3 months of therapy on medium-dose inhaled corticosteroids plus a second asthma controller or high-dose inhaled corticosteroids alone

    3. ​One or more asthma exacerbations in the previous 12 months requiring treatment with systemic corticosteroids

    4. ​Pre-screening FEV1 <95% of predicted

    ​5. Patients currently on Xolair are not eligible

  4. Phase 4 Research Study: Observational study of patients with a diagnosis of asthma and/or COPD (observation period of 3 years)

    1. Subjects ≥12 years of age with a confirmed or suspected diagnosis of asthma or COPD

    2. Observational study only (no study medications)

  5. Phase 3 study to evaluate the effect of trial medication on the AAER lung function, and asthma control in adults and adolescents with uncontrolled asthma. Male or Female 12-80 years of age

    1. Documented Asthma for at least 12 months

    2. Patient must have been on a physician prescribed asthma controller for at least 12 months

  6. Phase 3 study to evaluate the effect of trial medication on patients with severe nasal polyps. Male or Female 18-75 years of age

    A minimum bilateral sinnonasal polyposis, that despite treatment with INCS have severity consisitent with the need for surgery

  7. Phase 3 study comparing study drug to Spiriva Respimat in subjects with persistent asthma. Male or Female 18 years of age or older

    Pre-bronchodilator FEV1 of >40% and <80% predicted normal value

  8. Phase 3 study for patients with inadequately controlled asthma

    Male or Female patients 18 years of age or older

Call to Schedule an Appointment!

Lincoln: 402.464.5969          Omaha: 402.391.1800

  • Did you know?
    Depending on your degree of allergies, allergen avoidance steps and medications by themselves may not be entirely effective in managing your symptoms.
    View Pollen Count

MENU CLOSE